Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327648 | 0.81 | SMN1; SMN2 (0.41) | ALDH1A1CYP3A4SMN1; SMN2CYP1A2PPARA | |
| SCHEMBL276630 | 0.77 | TRPA1 (0.43) | ALDH1A1MAPTCYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL25015331 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MAPTCYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL1965917 | 0.72 | SMN1; SMN2 (0.51) | ALDH1A1MAPTCYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL277081 | 0.72 | SMN1; SMN2 (0.48) | ALDH1A1MAPTCYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL25179993 | 0.72 | SMN1; SMN2 (0.48) | ALDH1A1MAPTCYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL2222084 | 0.71 | SMN1; SMN2 (0.44) | ALDH1A1MAPTCYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL8099629 | 0.71 | MAPT (0.48) | ALDH1A1MAPTSMN1; SMN2TSHRMEN1 | |
| SCHEMBL8193467 | 0.71 | SMN1; SMN2 (0.50) | ALDH1A1MAPTCYP3A4SMN1; SMN2CYP1A2 | |
| SCHEMBL20263132 | 0.71 | SMN1; SMN2 (0.50) | ALDH1A1MAPTCYP3A4SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133904-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8088798-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | Jensen Discovery, Inc. | 2012-01-03 | — | — | US | disclosed |
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2010-06-10 | — | — | US | disclosed |
| US-7687481-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | JENRIN DISCOVERY (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | JENRIN DISCOVERY (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | ALDH1A1 3407/4885MAPT 4267/4885CYP3A4 1129/4885 |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | ALDH1A1 3407/4885MAPT 4267/4885CYP3A4 1129/4885 |
| US-20070213302-A1 | pyrazoles; diabetes, cardiometabolic disorders; side effects reduction | CNR2, CNR1, GPR119 | ALDH1A1 2408/4885MAPT 4569/4885CYP3A4 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.